Robert A. Copeland, Chief Scientific Officer, to provide major symposium presentation on inhibition of key RNA-modifying enzymes as precision cancer therapeutics Preclinical data validate DHX9 as a new target in breast cancer and other solid tumors with loss-of-function mutations in the…